Juno Therapeutics (NASDAQ:JUNO) Rating Change

Juno Therapeutics (NASDAQ:JUNO) was downgraded by investment analysts at Wells Fargo from Outperform rating to Market Perform rating in a research report shared with investors and clients on 12 December.

The company’s rating downgrade is noticed by equity trades, as NASDAQ:JUNO is right now trading -0.12% lower at $58.70 as of 4:07 PM New York time. Juno Therapeutics’s stock is 0% over the last 200 days. It has underperformed the S&P500 Index, which has gained 6.00% over the same time.

Out of 11 analysts covering Juno Therapeutics, 0 rate it a Buy, 0 indicate a Hold while 0 suggest a Sell. The highest target is $80 and the lowest is $39 according to Thomson/First Call. The 12-month mean target is $55.73, which means downside potential of 5.06% over the current price.

Institutional Ownership

Sib Llc had the most significant stake with ownership of 100,000 shares as of q2 2015 for 2.42% of the US equity exposure. Bb Biotech Ag is another quite bullish active investment manager who is having 1.41M shares of Juno Therapeutics or 1.48% of their US equity exposure. Moreover, Duquesne Family Office Llc have 1.31% of their US equity exposure invested in the company for 493,000 shares. The Washington-based fund First Washington Corp disclosed it had acquired so far a stake worth about 1.1% of the active investment manager’s stock portfolio in Juno Therapeutics. The California-based fund Partner Fund Management L.P. is also positive about the stock, possessing 65,320 shares or 0.99% of their US equity exposure.

Juno Therapeutics (NASDAQ:JUNO) Profile

Juno Therapeutics, Inc. (Juno) is a biopharmaceutical company, which is focused on developing cellular immunotherapies for the treatment of cancer. The Company is developing cell-based cancer immunotherapies based on its chimeric antigen receptor (CAR) and T cell receptor (TCR) technologies to genetically engineer T cells to recognize and kill cancer cells. Its product candidates JCAR017, JCAR014, and JCAR015, as well as an additional early stage product candidate incorporating a fully human binding domain, leverage CAR technology to target CD19, a protein expressed on the surface of almost all B cell leukemias and lymphomas.

Juno Therapeutics (NASDAQ:JUNO) traded down -0.12% on 12 December, hitting $58.7. A total of 1.67 million shares of the company’s stock traded hands. This is down from average of 2.18 million shares. Juno Therapeutics has a 52 week low of $17.52 and a 52 week high of $61.59. The company has a market cap of $6.71 billion and a P/E ratio of 0.

Get the latest Juno Therapeutics (NASDAQ:JUNO) Stock Ratings at Octafinance. Completely free access to our Analyst Ratings Database for 6000+ stocks.

The post Juno Therapeutics (NASDAQ:JUNO) Decreased by Analysts at Wells Fargo to Market Perform from Outperform Rating appeared first on Octafinance.